TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00603109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: rimonabant capsule 20 mg per day PO for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects take 20 mg placebo capsule one a day PO for 6 months
Study: NCT02270619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Description: Partial night sleep deprivation by staying awake from 23:00 to 03:00

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation
Description: Partial night sleep deprivation by staying awake from 23:00 to 03:00

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% saline as IV bolus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline as IV bolus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uninterrupted sleep
Description: Uninterrupted sleep from 23:00 to 07:00

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Uninterrupted sleep
Description: Uninterrupted sleep from 23:00 to 07:00
Study: NCT02275078

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: COPD self-management using an action plan
Description: Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.~Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.

Intervention type: DEVICE
Group type: OTHER
Intervention: Telesystem-Phone self-assessment/reporting system
Description: Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse case manager support
Description: Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
Study: NCT04342871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT
Description: Customized communication guidance to help parents with cancer talk about their cancer with their children.
Study: NCT04620044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaledo game
Description: Before starting the study, the height and weight of the children in the play group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the game sessions were started.Game sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Before starting the study, the height and weight of the children in the education group were measured and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.Then the education sessions were started.education sessions lasted 12 weeks. After 12 weeks, the height and weight measurements of the students were made and their body mass indexes were calculated. Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Body mass indexes were calculated by measuring the height and weight of the students.Personal information form, nutrition self-efficacy scale, nutrition attitude scale and nutrition behavior scale were applied.The same measurements and scale applications were repeated after 12 weeks.
Study: NCT03012087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHealthyChoices
Description: My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Risk Assessment
Description: The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
Study: NCT02031562

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chiropractic
Description: chiropractic

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: physical therapy
Study: NCT02004496

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Consilium
Description: Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Consilium
Description: Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
Study: NCT01511276

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mainly exercise induced weight loss
Description: Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.~Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day.
Study: NCT02808754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic \> 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
Study: NCT03832491

Intervention type: OTHER
Group type: OTHER
Intervention: Home based therapy
Description: Airway clearence techniques

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game and home based therapy
Description: Game based approach programme and airway clearence techniques
Study: NCT04391348

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET-TDM with 18F-FDG + PET-TDM with 18F-fluorocholine
Description: Experimental procedure combining PET-TDM with 18F-FDG and PET-TDM with 18F-Fluorocholine
Study: NCT03103802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-oral digital scanner and extra-oral digital scanner
Description: intra-oral and extra-oral digital scanners used to obtain digital models

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-oral digital scanner and extra-oral digital scanner
Description: intra-oral and extra-oral digital scanners used to obtain digital models

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-oral digital scanner and extra-oral digital scanner
Description: intra-oral and extra-oral digital scanners used to obtain digital models

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-oral digital scanner and extra-oral digital scanner
Description: intra-oral and extra-oral digital scanners used to obtain digital models

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intra-oral digital scanner and extra-oral digital scanner
Description: intra-oral and extra-oral digital scanners used to obtain digital models
Study: NCT03284684

Intervention type: OTHER
Intervention: Blood test
Description: plasma concentration of circulating DNA of specific genes
Study: NCT02180555

Intervention type: OTHER
Intervention: Oral glucose tolerance test
Study: NCT01611974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Tablet for oral administration
Study: NCT03854864

Intervention type: OTHER
Intervention: survey
Description: to assess the current practices of management by oncologists in France in 2019, for any type of practitioners of university hospital, or general hospital, for all type of neurotoxic anticancer drugs.
Study: NCT01620931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5469754
Description: Single ascending doses, iv or sc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses, iv or sc
Study: NCT02116556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin PO 1200 mg/day for 90 days
Study: NCT00518037

Intervention type: BEHAVIORAL
Intervention: surveys
Description: anxiety surveys
Study: NCT02250820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Nasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Description: Oral administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Oral placebo will be cherry syrup

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Placebo
Description: Nasal placebo will be nasally atomized saline
Study: NCT02176473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy
Description: The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/.
Study: NCT01423409

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pictorial VAS
Description: Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: usual VAS
Description: usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
Study: NCT02603874

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Target Tape
Description: Comparing procedures using Target Tape against procedures not using Target Tape
Study: NCT04022915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-FBP8
Description: Up to 10 mCi (millicurie) 64Cu-FBP8 will be administered to each subject.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET-CT imaging
Description: All subjects will undergo PET-CT imaging after administration of 64Cu-FBP8.
Study: NCT04464395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-006
Description: Participants will receive a single dose of CPI-006 at one of four dose levels (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 5.0 mg/kg) along with standard of care.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Participants will receive standard of care treatment only.
Study: NCT02257372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC DPI
Description: The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA medication
Description: Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICS/LABA medication
Description: Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol Metered Dose Inhaler (MDI)
Description: Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
Study: NCT00003535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a recurrent/progressive high grade glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT03194282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: insole
Description: The subjects are randomly assigned to assess balance capacity either with or without insole.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: insole
Description: The subjects are randomly assigned to assess balance capacity either with or without insole.
Study: NCT02672436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENERGI-F703
Description: Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ENERGI-F703 matched vehicle
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Study: NCT02289742

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A multifocal contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A toric contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A sphere contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A sphere contact lenses
Study: NCT04136873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-231
Description: CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-231
Study: NCT01366547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir 600 mg/lamivudine 300 mg
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Study: NCT01030770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
Study: NCT02952157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine jelly application

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal saline application
Study: NCT01279577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose TSO
Description: Low dose TSO suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose TSO
Description: Medium dose TSO suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose TSO
Description: High dose TSO suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution
Study: NCT02211729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
Description: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin
Description: Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
Study: NCT00914927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag first Dose 80 mg followed by 10 mg a day for up to 6 additional days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Avatrombopag first Dose 80 mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo or inactive substance once a day for up to 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or inactive substance once a day for up to 7 days
Study: NCT01323725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team-based financial incentives
Description: Team-based financial incentives for smoking cessation at 6 month post-quit date.
Study: NCT03844984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine full dose
Description: This group will receive induction of anesthesia using Ketamine 1 mg/Kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: This group will receive midazolam 0.05 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: This group will receive normal saline 10 mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine half dose
Description: This group will receive induction of anesthesia using Ketamine 0.5 mg/Kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: This group will receive lidocaince 1 mg/Kg diluted in 10 mL normal saline.